Purinergic receptors modulate MAP kinases and transcription factors that control microglial inflammatory gene expression.
Following many types of brain injury, microglial cell hyperactivation, and the subsequent release of neurotoxic mediators into the CNS contributes to inflammation and neuronal death. Among the proteins important for modulating the inflammatory function of microglia are the P2 purinergic receptors for which extracellular adenine nucleotides, such as ATP, are ligands. Because adenine nucleotides are abundant in the extracellular fluid following brain injury, ATP may represent an important component of the inflammatory microenvironment controlling microglial cell function. Although much work has been done examining the mechanisms whereby adenine nucleotides stimulate inflammatory mediator production, little is known concerning their complementary inhibitory effects. In this review we will focus on what is currently known about the microglial inhibitory effects of adenine nucleotides in the context of inflammation and summarize the current knowledge of their effects via purinergic receptors on microglial signal transduction pathways including transcription factors important for controlling inflammatory gene expression. The relevance of these mechanisms to microglial inflammatory function and physiology will be discussed. Further, we present data here illustrating that MAP kinase signal transduction pathways are altered in activated microglia that have been primed with or co-exposed to adenine nucleotides; effects that are stimulus- and MAPK pathway-specific. We also demonstrate the ability of P2X7 receptors to stimulate the phosphorylation of CREB, a putative inhibitory transcription factor in microglia. Together, these data indicate that ATP may be an endogenous inhibitor or neuroprotective molecule decreasing the inflammatory capacity of microglia.
Potucek
Yvonne D
YD
Department of Comparative Biosciences and Program in Cellular and Molecular Biology, University of Wisconsin, Madison, WI 53706, United States.
Crain
Jessica M
JM
Watters
Jyoti J
JJ
D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D001925:Brain Damage, Chronic / Q000235:genetics* / Q000276:immunology / Q000378:metabolism; D019610:Cytoprotection / Q000235:genetics / Q000276:immunology; D004660:Encephalitis / Q000235:genetics* / Q000276:immunology / Q000378:metabolism; D005786:Gene Expression Regulation / Q000235:genetics / Q000276:immunology; D005911:Gliosis / Q000235:genetics* / Q000276:immunology / Q000378:metabolism; D006801:Humans; D020935:MAP Kinase Signaling System / Q000235:genetics / Q000276:immunology; D017628:Microglia / Q000276:immunology / Q000378:metabolism*; D011983:Receptors, Purinergic / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D014157:Transcription Factors / Q000235:genetics / Q000276:immunology
D011983:Receptors, Purinergic; D014157:Transcription Factors; D000255:Adenosine Triphosphate